FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:750-752 March 16, 1995 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Spector, S. A. PubMed Citation

To the Editor: Two double-blind, placebo-controlled trials have demonstrated that intravenous immune globulin reduces serious and minor bacterial infections and hospitalizations in children infected with the human immunodeficiency virus (HIV) who have early or advanced disease, including those receiving zidovudine.^1,2,3 The results of the National Institute of Child Health and Human Development (NICHHD) trial contrast with those of a subgroup analysis in AIDS Clinical Trials Group (ACTG) Protocol 051, reported by Spector et al. (Nov. 3 issue).¹ According to the subgroup analysis, a significant benefit of intravenous immune globulin appeared to be confined to the 174 patients not receiving trimethoprim–sulfamethoxazole . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.